With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the potential.

Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission for Ziihera for biliary tract cancer.

The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...

Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some experts.

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

Piramal Pharma invests $90m to expand its two US facilities, enhancing manufacturing capabilities for sterile injectables and ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...

WHO director Dr Tedros Adhanom Ghebreyesus says all hypotheses are on the table, as the organisation works to reinforce ...